SI0802909T1 - Substituted oxazolidine calpain and/or cathepsin b inhibitors - Google Patents

Substituted oxazolidine calpain and/or cathepsin b inhibitors

Info

Publication number
SI0802909T1
SI0802909T1 SI9530539T SI9530539T SI0802909T1 SI 0802909 T1 SI0802909 T1 SI 0802909T1 SI 9530539 T SI9530539 T SI 9530539T SI 9530539 T SI9530539 T SI 9530539T SI 0802909 T1 SI0802909 T1 SI 0802909T1
Authority
SI
Slovenia
Prior art keywords
calpain
cathepsin
inhibitors
substituted oxazolidine
oxazolidine
Prior art date
Application number
SI9530539T
Other languages
English (en)
Slovenian (sl)
Inventor
Norton P. Peet
Shujaath Mehdi
Matthew D. Linnik
Michael R. Angelastro
Hwa-Ok Kim
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of SI0802909T1 publication Critical patent/SI0802909T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9530539T 1995-01-11 1995-12-15 Substituted oxazolidine calpain and/or cathepsin b inhibitors SI0802909T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37119295A 1995-01-11 1995-01-11
EP95943478A EP0802909B1 (en) 1995-01-11 1995-12-15 Substituted oxazolidine calpain and/or cathepsin b inhibitors
PCT/US1995/016565 WO1996021655A2 (en) 1995-01-11 1995-12-15 Substituted oxazolidine calpain and/or cathepsin b inhibitors

Publications (1)

Publication Number Publication Date
SI0802909T1 true SI0802909T1 (en) 2002-02-28

Family

ID=23462894

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530539T SI0802909T1 (en) 1995-01-11 1995-12-15 Substituted oxazolidine calpain and/or cathepsin b inhibitors

Country Status (23)

Country Link
US (1) US5691368A (zh)
EP (1) EP0802909B1 (zh)
JP (1) JP4157601B2 (zh)
KR (1) KR100393701B1 (zh)
CN (1) CN1088456C (zh)
AR (1) AR001787A1 (zh)
AT (1) ATE206413T1 (zh)
AU (1) AU692044B2 (zh)
CA (1) CA2210258C (zh)
DE (1) DE69523072T2 (zh)
DK (1) DK0802909T3 (zh)
ES (1) ES2165441T3 (zh)
FI (1) FI972935A (zh)
HU (1) HUT77649A (zh)
IL (1) IL116724A (zh)
MX (1) MX9705235A (zh)
NO (1) NO309267B1 (zh)
NZ (1) NZ298999A (zh)
PT (1) PT802909E (zh)
SI (1) SI0802909T1 (zh)
TW (1) TW454001B (zh)
WO (1) WO1996021655A2 (zh)
ZA (1) ZA96100B (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270882B (it) * 1993-10-05 1997-05-13 Isagro Srl Oligopeptidi ad attivita' fungicida
US5925633A (en) * 1996-03-06 1999-07-20 Synphar Laboraties, Inc. 3-Substituted-4-oxa-1-azabicyclo 3,2,0!heptan-7-one as cysteine protease inhibitors
AU6134498A (en) * 1997-03-07 1998-09-22 Hoechst Marion Roussel, Inc. Method of treating trauma associated with brain, spinal cord or peripheral nerveinjury using carbobenzyloxy n-protected di- and tripeptide phenylalaninals
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
JP2002529422A (ja) * 1998-11-12 2002-09-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 虚血により傷害を受けた組織の処置法
CA2360740A1 (en) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
EP1516877A1 (en) * 1999-03-15 2005-03-23 Axys Pharmaceuticals, Inc. Amine derivatives as protease inhibitors
WO2000055124A2 (en) 1999-03-15 2000-09-21 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
TW200404789A (en) * 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
FR2800737B1 (fr) * 1999-11-05 2006-06-30 Sod Conseils Rech Applic Nouveaux composes heterocycliques et leur application a titre de medicaments
KR100725198B1 (ko) 1999-11-05 2007-06-07 소시에떼 드 꽁세이으 드 르세르세 에 따블리까시옹 시앙띠피끄 (에스.세.에르.아.에스.) 신규 헤테로시클릭 화합물 및 의약으로서의 용도
AU2001278084A1 (en) * 2000-07-31 2002-02-13 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
EP1383748A2 (en) 2000-12-22 2004-01-28 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
EP1436255A1 (en) 2001-09-14 2004-07-14 Aventis Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
CA2467391A1 (en) 2001-11-14 2003-05-22 Aventis Pharmaceuticals Inc. Oligopeptides and compositions containing them as cathepsin s inhibitors
WO2004084830A2 (en) * 2003-03-21 2004-10-07 Buck Institute Method for treating alzheimer’s dementia
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
WO2004089395A2 (en) * 2003-04-01 2004-10-21 Aventis Pharmaceuticals Inc. Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
FR2863268B1 (fr) * 2003-12-09 2006-02-24 Sod Conseils Rech Applic Nouveaux derives du 2-hydroxytetrahydrofuranne et leur application a titre de medicaments
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
KR20090115951A (ko) 2007-03-01 2009-11-10 프로비오드룩 아게 글루타미닐 사이클라제 저해제의 신규 용도
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2300000A1 (en) * 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
WO2024018245A1 (en) 2022-07-22 2024-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of calpain inhibitors for the treatment of the diabetic kidney disease
WO2024153744A1 (en) 2023-01-20 2024-07-25 Institut National de la Santé et de la Recherche Médicale Autophagy activators for the treatment of rhabdomyolysis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867364A (en) * 1968-11-21 1975-02-18 Microbial Chem Res Found Process for the synthesis of leupeptins and their analogues
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4277395A (en) * 1980-06-16 1981-07-07 Richardson-Merrell Inc. Novel enzyme inhibitors
JPS5754157A (en) * 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
US4535167A (en) * 1981-12-14 1985-08-13 Merck & Co. Inc. Chiral, N-protected, N-substituted α-amino acids
WO1984000365A1 (en) * 1982-07-19 1984-02-02 Nat Res Dev Synthetic peptides and their preparation
US4845079A (en) * 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5214129A (en) * 1985-01-23 1993-05-25 Abbott Laboratories Peptidylaminodiols
US5091575A (en) * 1985-01-23 1992-02-25 Abbott Laboratories Peptidylaminodiols
US5496927A (en) * 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
JPH079705B2 (ja) * 1986-05-28 1995-02-01 オリンパス光学工業株式会社 光カ−ド用デ−タ記録再生装置
EP0264106B1 (en) * 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use
US5032577A (en) * 1986-12-31 1991-07-16 Abbott Laboratories Peptidylaminodiols
NZ223148A (en) * 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity
US4820691A (en) * 1987-06-24 1989-04-11 E. R. Squibb & Sons, Inc. Amino acid 1,2-diketo derivatives as renin inhibitors
EP0313847A3 (en) * 1987-10-01 1989-11-29 G.D. Searle & Co. Non-peptidyl alpha-succinamidoacyl aminodiols as anti-hypertensive agents
WO1989007109A1 (en) * 1988-02-01 1989-08-10 The Upjohn Company Renin inhibiting peptides with polar end groups
HUT58764A (en) * 1988-07-08 1992-03-30 Smithkline Beckman Corp Process for producing peptides, pharmaceutical compositions containing them and amino-acid intermediates
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US4990525A (en) * 1988-12-22 1991-02-05 Rohm And Haas Company Synergistic microbicidal combinations containing 3-isothiazolone and commerical biocides
US5510531A (en) * 1989-04-10 1996-04-23 Suntory Limited Proteinase inhibitor
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
EP0532693A1 (en) * 1990-06-01 1993-03-24 The Du Pont Merck Pharmaceutical Company 1,4-diamino-2,3-dihydroxybutanes
DE4037437A1 (de) * 1990-11-24 1992-05-27 Hoechst Ag Aminodiol-derivate
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
JPH06504061A (ja) * 1990-12-28 1994-05-12 コーテックス　ファーマシューティカルズ　インコーポレイテッド 神経変性の治療および予防におけるカルパイン阻害剤の使用
EP0564561A4 (en) * 1990-12-28 1994-08-10 Georgia Tech Res Inst Peptides ketoamides, ketoacids, and ketoesters
CA2071621C (en) * 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
JP3190431B2 (ja) * 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
ZA926185B (en) * 1991-08-22 1993-03-01 Merrell Dow Pharma Novel orally-active elastase inhibitors.
EP0580161A1 (en) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Prophylactic and therapeutic treatment of Alzheimer's disease
DK0603769T3 (da) * 1992-12-25 1999-06-14 Mitsubishi Chem Corp Alfa-aminoketonderivater
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5541290A (en) * 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
CN1078886C (zh) * 1993-10-01 2002-02-06 默里尔药物公司 抑制β－淀粉样蛋白产生的抑制剂

Also Published As

Publication number Publication date
IL116724A (en) 2000-08-31
NZ298999A (en) 1999-01-28
DK0802909T3 (da) 2002-01-28
EP0802909A2 (en) 1997-10-29
JP4157601B2 (ja) 2008-10-01
JPH10512257A (ja) 1998-11-24
TW454001B (en) 2001-09-11
EP0802909B1 (en) 2001-10-04
AR001787A1 (es) 1997-12-10
NO973216L (no) 1997-09-09
US5691368A (en) 1997-11-25
AU4473196A (en) 1996-07-31
NO309267B1 (no) 2001-01-08
ATE206413T1 (de) 2001-10-15
PT802909E (pt) 2002-03-28
CN1088456C (zh) 2002-07-31
CA2210258A1 (en) 1996-07-18
DE69523072T2 (de) 2002-06-20
ES2165441T3 (es) 2002-03-16
FI972935A0 (fi) 1997-07-10
ZA96100B (en) 1996-07-24
KR100393701B1 (ko) 2003-11-28
WO1996021655A2 (en) 1996-07-18
IL116724A0 (en) 1996-05-14
MX9705235A (es) 1997-10-31
NO973216D0 (no) 1997-07-10
HUT77649A (hu) 1998-07-28
CA2210258C (en) 2002-10-01
DE69523072D1 (en) 2001-11-08
FI972935A (fi) 1997-07-10
CN1173174A (zh) 1998-02-11
AU692044B2 (en) 1998-05-28
WO1996021655A3 (en) 1996-09-06

Similar Documents

Publication Publication Date Title
ZA96100B (en) Substituted oxazolidine calpain and/or cathepsin b inhibitors
PL326508A1 (en) Protease inhibitors
HUP0000475A3 (en) Ketobenzamides as calpain inhibitors
EP0835109A4 (en) PYRIDINONE-BASED THROMBIN INHIBITORS
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
EP0820453A4 (en) THROMBIN INHIBITORS
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
PL327569A1 (en) Promedications of thrombosin inhibitors
HU9601508D0 (en) Dp-iv-serine protease inhibitors
HU9202842D0 (en) Climotripsine-type proteases and inhibitors
EP0744948A4 (en) PROTEASE INHIBITORS
IL121167A0 (en) Method of inhibiting cathepsin K
IL117638A0 (en) Reversible protease inhibitors
EP0831920A4 (en) NOVEL CATHEPSIN AND METHODS AND COMPOSITIONS FOR INHIBITING CATHEPSIN
GB9624731D0 (en) Complement inhibitor
HUP9802764A3 (en) Guanidino protease inhibitors
HU9503783D0 (en) Squvalen syntetase inhibitors
IL117437A0 (en) Novel thrombin inhibitors
ZA946325B (en) Retroviral protease inhibitors and combinations thereof.
EP0835123A4 (en) AMINOPEPTIDASE P INHIBITORS AND USES THEREOF
DE69523450D1 (en) Inhibitor
EP0868913A4 (en) INTIMAL THICKENING INHIBITOR
IL112244A0 (en) Novel inhibitor
BR9303279A (pt) Inibição de nitrosamina e nitreto
GB9500946D0 (en) Protease inhibitors